IOL Chemicals & Pharmaceuticals Ltd Q1 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/11lkjrwepvcpu5lo4uegwjy9.pdf

Key Takeaways


Topline: Flat Revenue, Shifting Mix

Mahajan: "This development is under the process already and it took maybe two quarters or three quarters, will start getting benefits from export markets probably in 8 to 9 months."

Margins: Gross Margin Up, EBITDA Guarded

Singh: "We cannot comment that we will be achieving the 20%–22% EBITDA margin in this fiscal year or the next fiscal year, but I think something around 15% to 17% is sustainable."

Non-Ibuprofen APIs: The Next Leg

Mahajan: "As of now, you can say single digit EBITDA margin as of now, but with the capacity enhancement with full utilization and getting the export market, we hope for at par with the ibuprofen margins."

Backward Integration & Capacity

Mahajan: "I think that IOL is the only company which is 100% backward integrated with para-aminophenol and Acetic anhydride. We think no other company is 100% backward integrated."

Capital Allocation & Returns

Singh: "We are having certain shortlisted products. The R&D is continuously working on all these products and considering the viability and the market responses and the economies of scale, we will be coming out with the appropriate announcement after everything is finalized."

Guidance & Commitments

CommitmentSpecificsTimeline
Ibuprofen capacity utilization85%–90% sustainedFull year FY24
Non-ibuprofen API revenueMore than ₹500–550 croreFY24
Non-ibuprofen API growth rate~20%–25% YoYNext 2 years, then re-analyze
Non-ibuprofen API margin improvementDouble-digit EBITDA (at par with ibuprofen)2–3 quarters, when Europe exports begin
Export market benefitsIncremental business from Europe and regulated markets2–3 quarters (8–9 months)
Acetic anhydride merchant revenue~₹70 crore, peaking at ~₹125 croreFY24 / peak thereafter
Specialty chemical EBIT margin5%–6% rangeFull year FY24
Sustainable EBITDA margin15%–17%Ongoing; 20%–22% not committed for FY24 or FY25
CAPEX~₹250 crore, internally funded, no debtFY24
Paracetamol capacity expansion decisionClarity expectedEnd-Q2 or Q3 FY24
New product announcementsAfter R&D finalization and board approvalNo date

Key Metrics

MetricQ1 FY24
Total income₹570 cr, flat YoY
EBITDA₹79.9 cr, up 30.6% YoY from ₹61 cr; ₹105 cr in Q4 FY23
EBITDA margin14.0%, improved 330 bps YoY from 10.7%
Net profit₹46.2 cr, up from ₹34.9 cr YoY; ₹65.3 cr in Q4 FY23
EBIT margin – Pharmaceutical segment14.3%
EBIT margin – Specialty Chemical segment4.7%
Ibuprofen capacity utilization85%–90%, up from 65%–75% in June 22
Ibuprofen export split~34% of ibuprofen revenue
Non-ibuprofen API revenue target FY24₹500–550 cr, up from ~₹380 cr in FY23
Non-ibuprofen API export split~15%–20% export, ~80%–85% domestic
Paracetamol capacity utilization~90%
Acetic anhydride plant capacity utilization~80%, commissioned mid-June 2023; ~60% captive, ~40% merchant
Acetic anhydride merchant revenue target FY24₹70 cr, peak potential ~₹125 cr
CAPEX planned for FY24~₹250 cr, funded through internal accruals
Net cash₹260 cr as of 30th June 2023
Employee count2,725 as of 30th June 2023, up from ~2,300 in March 2023